Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

about

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Item

http://www.wikidata.org/entity/Q38745926

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Validation of the Association ...... r Treated on SWOG Study S0421.

@en

type

Item

label

Validation of the Association ...... r Treated on SWOG Study S0421.

@en

prefLabel

Validation of the Association ...... r Treated on SWOG Study S0421.

@en

P1476

Validation of the Association ...... r Treated on SWOG Study S0421.

@en

P2093

Amir Goldkorn

http://www.w3.org/2001/XMLSchema#string

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Celestia S Higano

http://www.w3.org/2001/XMLSchema#string

David I Quinn

http://www.w3.org/2001/XMLSchema#string

Gregory R Pond

http://www.w3.org/2001/XMLSchema#string

Guru Sonpavde

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

J Paul Monk

http://www.w3.org/2001/XMLSchema#string

Maha H A Hussain

http://www.w3.org/2001/XMLSchema#string

Mark G Garzotto

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

P31

scholarly article

P356

10.1016/J.CLGC.2017.05.014

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28579151

http://www.w3.org/2001/XMLSchema#string

P932

5734863

http://www.w3.org/2001/XMLSchema#string